1. Home
  2. GRFS vs PATH Comparison

GRFS vs PATH Comparison

Compare GRFS & PATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRFS
  • PATH
  • Stock Information
  • Founded
  • GRFS 1940
  • PATH 2005
  • Country
  • GRFS Spain
  • PATH United States
  • Employees
  • GRFS N/A
  • PATH N/A
  • Industry
  • GRFS Biotechnology: Pharmaceutical Preparations
  • PATH Computer Software: Prepackaged Software
  • Sector
  • GRFS Health Care
  • PATH Technology
  • Exchange
  • GRFS Nasdaq
  • PATH Nasdaq
  • Market Cap
  • GRFS 6.6B
  • PATH 6.5B
  • IPO Year
  • GRFS 2006
  • PATH 2021
  • Fundamental
  • Price
  • GRFS $9.11
  • PATH $14.29
  • Analyst Decision
  • GRFS Hold
  • PATH Hold
  • Analyst Count
  • GRFS 1
  • PATH 17
  • Target Price
  • GRFS $10.30
  • PATH $13.88
  • AVG Volume (30 Days)
  • GRFS 592.2K
  • PATH 32.0M
  • Earning Date
  • GRFS 01-01-0001
  • PATH 12-04-2025
  • Dividend Yield
  • GRFS 1.58%
  • PATH N/A
  • EPS Growth
  • GRFS 132.60
  • PATH N/A
  • EPS
  • GRFS 0.53
  • PATH 0.04
  • Revenue
  • GRFS $8,744,226,659.00
  • PATH $1,496,651,000.00
  • Revenue This Year
  • GRFS $5.46
  • PATH $12.26
  • Revenue Next Year
  • GRFS $6.69
  • PATH $8.85
  • P/E Ratio
  • GRFS $22.60
  • PATH $375.73
  • Revenue Growth
  • GRFS 9.32
  • PATH 8.25
  • 52 Week Low
  • GRFS $6.19
  • PATH $9.38
  • 52 Week High
  • GRFS $11.14
  • PATH $18.74
  • Technical
  • Relative Strength Index (RSI)
  • GRFS 36.85
  • PATH 44.51
  • Support Level
  • GRFS $9.14
  • PATH $15.41
  • Resistance Level
  • GRFS $9.50
  • PATH $16.58
  • Average True Range (ATR)
  • GRFS 0.29
  • PATH 1.02
  • MACD
  • GRFS -0.02
  • PATH -0.30
  • Stochastic Oscillator
  • GRFS 26.39
  • PATH 3.93

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

About PATH UiPath Inc.

UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.

Share on Social Networks: